Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
HOME > BUSINESS
BUSINESS
- MSD, Alfresa, Aerosense to Collaborate in Developing a Drug Delivery Business Using Drones
April 7, 2016
- Mylan Japan Labor Union Raps Management over “Effective Dismissal”, No Progress Made in 1st Round of Negotiations
April 6, 2016
- Daiichi Sankyo Joins Portola’s Factor Xa Antidote Consortium in Japan
April 6, 2016
- Daiichi Sankyo, Asahikawa Medical Univ. to Conduct Joint Research on New Stem Cells with Funding from Mitsubishi UFJ Capital
April 6, 2016
- JT, Torii Aim to File Japan NDA for Gilead’s Anti-HIV Drug in July-September
April 6, 2016
- Astellas Strikes New Research Pact with AIST for Chagas’ Disease
April 5, 2016
- GSK Keeps Its JCR Stake at 25%, Eyes Collaboration in Blood-Brain Barrier Technology
April 4, 2016
- Asahi Kasei Pharma Licenses TrkA Inhibitors from Array BioPharma
April 4, 2016
- Meiji Seika Pharma Gets Rights to Distribute Ultibro, Seebri in Japan; Novartis to Continue Copromotion
April 4, 2016
- Astellas Completes Transfer of Dermatology Biz to LEO Pharma
April 4, 2016
- Ex-Pfizer Japan Exec Matsumori to Lead Takeda-Teva JV
April 4, 2016
- Nichi-Iko Gets Global Rights to Rituximab Biosimilar from S. Korea’s Aprogen
April 4, 2016
- Sakigake: Now and Future (5) - BioCryst’s BCX7353 Would Be Japan’s 1st Drug for Preventing Angioedema Attacks
April 4, 2016
- Daiichi Sankyo Files NDA for Hydromorphone, Standard Pain Therapy Outside Japan
April 1, 2016
- Towa Prevails in Patent Suit over Elplat
April 1, 2016
- Novartis to Sell 14 Long-Listed Brands to Sun Pharma in Japan, Likely to Stop Aredia Sales
April 1, 2016
- Daiichi Sankyo Eyes V-Shaped Recovery from Olmesartan Patent Cliff: 5-Year Plan
April 1, 2016
- Eisai Gives Rights for Cancer Drug to Dr. Reddy’s Outside Japan, Asia
April 1, 2016
- Gilead Files Japan NDA for Tenofovir Prodrug for Chronic Hep B
April 1, 2016
- Janssen Seeks MCL Indication for Imbruvica
April 1, 2016
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…